{"id":30766,"date":"2025-01-09T18:04:26","date_gmt":"2025-01-09T12:34:26","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30766"},"modified":"2025-01-09T18:04:27","modified_gmt":"2025-01-09T12:34:27","slug":"medtech-news-of-roche-nanovibronix-hologic","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic","title":{"rendered":"Roche Secures FDA Clearance for High-Volume Slide Scanner; Pacira Gets 510(k) Approval for Iovera\u00b0 SmartTip for Chronic Back Pain; ClearCut Presents Clearcoast\u2122 Study Results at San Antonio Breast Cancer Symposium; NanoVibronix Completes UroShield\u00ae Pilot Study at University of Michigan; Hologic Finalizes Acquisition of Gynesonics; Movano Health Launches EvieAI Virtual Wellness Assistant."},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0808f2d85fd\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0808f2d85fd\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic\/#Roches_Momentum_in_Digital_Pathology_Continued_With_FDA_Clearance_on_its_High-Volume_Slide_Scanner\" >Roche&#8217;s Momentum in Digital Pathology Continued With FDA Clearance on its High-Volume Slide Scanner&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic\/#Pacira_BioSciences_Received_FDA_510k_Clearance_for_its_new_Iovera%C2%B0_SmartTip_Designed_to_Manage_Chronic_Low_Back_Pain_Through_a_Long-Lasting_Medial_Branch_Nerve_Block\" >Pacira BioSciences Received FDA 510(k) Clearance for its new Iovera\u00b0 SmartTip, Designed to Manage Chronic Low Back Pain Through a Long-Lasting Medial Branch Nerve Block&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic\/#ClearCut_Medical_Announced_the_Results_of_a_Post-Marketing_Clearcoast%E2%84%A2_Study_Presented_at_the_San_Antonio_Breast_Cancer_Symposium\" >ClearCut Medical Announced the Results of a Post-Marketing Clearcoast\u2122 Study, Presented at the San Antonio Breast Cancer Symposium&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic\/#NanoVibronix_Announced_the_Completion_of_Pilot_Phase_of_Clinical_Study_of_UroShield%C2%AE_at_the_University_of_Michigan\" >NanoVibronix Announced the Completion of Pilot Phase of Clinical Study of UroShield\u00ae at the University of Michigan<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic\/#Hologic_Completed_the_Acquisition_of_Gynesonics_Inc\" >Hologic Completed the Acquisition of Gynesonics, Inc.&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic\/#Movano_Health_Launched_EvieAI_Virtual_Wellness_Assistant\" >Movano Health Launched EvieAI Virtual Wellness Assistant&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-s-momentum-in-digital-pathology-continued-with-fda-clearance-on-its-high-volume-slide-scanner-nbsp\"><span class=\"ez-toc-section\" id=\"Roches_Momentum_in_Digital_Pathology_Continued_With_FDA_Clearance_on_its_High-Volume_Slide_Scanner\"><\/span>Roche&#8217;s Momentum in Digital Pathology Continued With FDA Clearance on its High-Volume Slide Scanner&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>January 09, 2025<\/strong>, Roche announced that its whole slide imaging system, Roche Digital Pathology Dx, received an additional 510(k) clearance from the United States Food and Drug Administration (FDA). This clearance modified the one Roche had previously obtained on June 14, 2024, for Roche Digital Pathology Dx, which included the VENTANA DP 200 slide scanner, Roche&#8217;s digital pathology workflow software, and a display, and now incorporated the VENTANA DP 600 slide scanner.<\/p>\n\n\n\n<p>The VENTANA DP 600 offered 40 times the capacity of the VENTANA DP 200 while utilizing the same scanning technology, ensuring pathologists received consistent, high-quality images from both systems. Roche Digital Pathology Dx included the VENTANA DP 200 slide scanner, the VENTANA DP 600 slide scanner, Roche&#8217;s digital pathology workflow software, and a display.<\/p>\n\n\n\n<p>Roche Digital Pathology Dx was designed to assist pathologists in reviewing and interpreting digital images of scanned pathology slides prepared from formalin-fixed paraffin-embedded (FFPE) tissue for patient diagnoses.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;The VENTANA DP 600 high-capacity slide scanner creates high-resolution, digital images of stained tissue samples that help clinicians diagnose cancer and determine a patient&#8217;s treatment,&#8221; <\/em>said Jill German, Head of Pathology Lab for Roche Diagnostics.<em> &#8220;The recent FDA clearances continue our momentum to advance the pathology lab&#8217;s digital transformation and reinforce our commitment to enhance patient care and healthcare efficiency through streamlining the digital workflow.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>As per DelveInsight\u2019s <strong>\u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/diagnostic-imaging-equipment-market\" class=\"ek-link\">Diagnostic Imagin<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diagnostic-imaging-equipment-market\" class=\"ek-link\"><strong>g Equipment<\/strong><\/a> <strong>&#8211; Market Insights, Competitive Landscape, and Market Forecast &#8211; 2030\u201d<\/strong>, the global diagnostic imaging equipment market was valued at <strong>USD 24.15 billion<\/strong> in 2023 growing at a <strong>CAGR<\/strong> of <strong>5.10%<\/strong> during the forecast period from 2024 to 2030, to reach <strong>USD 33.56 billion <\/strong>by 2030. The demand for diagnostic imaging equipment is primarily attributed to the rising technological advancement, growing burden of chronic diseases, increasing patient awareness regarding early-stage diagnosis, growing demand for effective &amp; efficient imaging technologies for diagnosis, and increasing geriatric population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pacira-biosciences-received-fda-510-k-clearance-for-its-new-iovera-smarttip-designed-to-manage-chronic-low-back-pain-through-a-long-lasting-medial-branch-nerve-block-nbsp\"><span class=\"ez-toc-section\" id=\"Pacira_BioSciences_Received_FDA_510k_Clearance_for_its_new_Iovera%C2%B0_SmartTip_Designed_to_Manage_Chronic_Low_Back_Pain_Through_a_Long-Lasting_Medial_Branch_Nerve_Block\"><\/span>Pacira BioSciences Received FDA 510(k) Clearance for its new Iovera\u00b0 SmartTip, Designed to Manage Chronic Low Back Pain Through a Long-Lasting Medial Branch Nerve Block&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>January 07, 2025,<\/strong> Pacira BioSciences, Inc., a leading provider of innovative non-opioid pain therapies, announced that it received clearance from the U.S. Food &amp; Drug Administration (FDA) to market a Smart Tip designed for accessing the medial branch nerves to manage chronic low back pain.<\/p>\n\n\n\n<p>The iovera system was an innovative, FDA-cleared, drug-free treatment that relieved pain through cryoneurolysis\u2014a process in which focused cold therapy was applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals. Pain relief was typically experienced immediately after treatment, with effects lasting for months as the nerve gradually regenerated.<\/p>\n\n\n\n<p>Previously, the iovera portfolio included either a three-pronged Smart Tip featuring 8.5-mm long 27-gauge needles for treating superficial nerves or a single, 90-mm long, 20-gauge Smart Tip suited for deeper nerves. It was most commonly used to treat knee pain but was also frequently employed to manage pain in the hip, shoulder, chest, foot, ankle, and other areas.<\/p>\n\n\n\n<p>A new 25-gauge, 180-mm Smart Tip was later introduced, enabling the treatment of deeper nerves such as the medial branch nerve. It was specifically designed to relieve chronic low back pain associated with facet-mediated pain. This longer-needle Smart Tip was uniquely constructed for use through a cannula or introducer, facilitating ice ball formation at deeper peripheral nerves.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA clearance of this new iovera\u00b0 Smart Tip is a pivotal step forward, offering patients an innovative, drug-free solution that delivers meaningful and lasting pain relief\u201d <\/em>said Jonathan Slonin, MD, Chief Medical Officer of Pacira BioSciences<em>. \u201cThis achievement reflects our dedication to improving quality of life for the millions of Americans living with chronic back pain.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>As per DelveInsight\u2019s <strong>\u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-stimulator-market\" class=\"ek-link\">Spinal Cord Stimula<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-stimulator-market\" class=\"ek-link\"><strong>tors<\/strong><\/a><strong> <\/strong>&#8211; <strong>Market Insights, Competitive Landscape, and Market Forecast &#8211; 2030\u201d<\/strong>, the global spinal cord stimulators market size was valued at <strong>USD 2.25 billion<\/strong> in 2023, growing at a <strong>CAGR<\/strong> of <strong>8.70%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 3.72 billion<\/strong> by 2030. The demand for spinal cord stimulators is primarily attributed to the growing number of patients with chronic pain, and neuropathic pain in the shoulder, legs, and knee. The technologically advanced devices that are non-invasive, eliminate targeted pains, and cause a reduction in patient discomfort, with no side effects are likely responsible for a boost in the global spinal cord stimulators market growth. Moreover, favorable government regulations for commercialization and launching products in the market and the rising geriatric population are some of the factors responsible for propelling the growth of the spinal cord stimulators market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clearcut-medical-announced-the-results-of-a-post-marketing-clearcoast-study-presented-at-the-san-antonio-breast-cancer-symposium-nbsp\"><span class=\"ez-toc-section\" id=\"ClearCut_Medical_Announced_the_Results_of_a_Post-Marketing_Clearcoast%E2%84%A2_Study_Presented_at_the_San_Antonio_Breast_Cancer_Symposium\"><\/span>ClearCut Medical Announced the Results of a Post-Marketing Clearcoast\u2122 Study, Presented at the San Antonio Breast Cancer Symposium&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>January 08<\/strong>, <strong>2025<\/strong>, ClearCut Medical, a commercial-stage privately held company, developed the ClearCoast\u2122, the first and only portable MRI system designed to perform real-time intraoperative margin assessment of excised breast tumors during Breast Conserving Surgery (BCS). Clear margins were critical for minimizing the risk of recurrence and the need for retreatment.<\/p>\n\n\n\n<p>The ClearCoast\u2122 portable MRI system, which provided surgeons with real-time information on margin assessment during Breast Conserving Surgery, was developed by ClearCut Medical Ltd.<\/p>\n\n\n\n<p>The study primarily aimed to compare retreatment proportions within and between study groups in accordance with the SSO-ASTRO guideline. The secondary endpoint compared the diagnostic ability of ClearCoast\u2122 and the Standard of Care (SoC) to detect positive margins intraoperatively, as well as the total excised breast tissue volume between study groups.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;ClearCoast\u2122 is the most promising technique currently available for intraoperative margin assessment in breast conserving surgery of in situ and invasive breast cancer&#8221; <\/em>said Prof. Dr. Marc Thill, director of the Department of Gynecology and Gynecological Oncology at the Agaplesion Markus Hospital in Frankfurt, Germany and PI of the study.<em> &#8220;Following previous trials and after using the technique in our interventional post-marketing ClearCoast\u2122 study, I am convinced that the technique is ready for clinical routine.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/breast-reconstruction-market\" class=\"ek-link\">Breast Recon<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/breast-reconstruction-market\" class=\"ek-link\"><strong>struction<\/strong><\/a><strong> <\/strong>&#8211; <strong>Market Insights, Competitive Landscape, and Market Forecast &#8211; 2030\u201d<\/strong>, the global breast reconstruction market was valued at <strong>USD 554.50 million<\/strong> in 2023, growing at a <strong>CAGR<\/strong> of <strong>6.54%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 810.14 million<\/strong> by 2030. The breast reconstruction market is witnessing positive growth owing to various factors such as the increasing prevalence of breast cancer, increase in the number of cosmetic &amp; reconstructive surgeries, surge in the launch of technologically advanced breast reconstruction products, and factors such as aging, race, &amp; ethnicity drives the breast reconstruction demand. Therefore, the market for breast reconstruction is estimated to grow at a significant CAGR during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-nanovibronix-announced-the-completion-of-pilot-phase-of-clinical-study-of-uroshield-at-the-university-of-michigan\"><span class=\"ez-toc-section\" id=\"NanoVibronix_Announced_the_Completion_of_Pilot_Phase_of_Clinical_Study_of_UroShield%C2%AE_at_the_University_of_Michigan\"><\/span>NanoVibronix Announced the Completion of Pilot Phase of Clinical Study of UroShield\u00ae at the University of Michigan<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>January 06<\/strong>, <strong>2025<\/strong>, NanoVibronix, Inc., a medical device company specializing in the UroShield\u00ae, PainShield\u00ae, and WoundShield\u00ae Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announced the successful completion of the first phase of a Randomized Control Trial study of UroShield\u00ae conducted by researchers at the University of Michigan (\u201cUM\u201d).<\/p>\n\n\n\n<p>This initial phase of the trial served as a precursor to the full study by UM researchers. It was carried out primarily with nursing home residents and focused on evaluating the impact of UroShield\u00ae on improving patients\u2019 quality of life by potentially reducing urinary tract infections, catheter blockages, and pain associated with the long-term use of urinary catheters.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Brian Murphy, Chief Executive Officer of the Company, commented,<em> \u201cThe first phase of the study served as a validation pilot in advance of a full study. With this phase now complete, researchers at UM can advance to the next phase, a full Randomized Control Trial of additional patients. We expect the full trial to commence in 2025.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Mr. Murphy continued,<em> \u201cThe validation our products continue to receive from independent research and the progress we are making towards further commercializing UroShield is highly encouraging. This research builds on previously concluded studies and product launches in the U.K., Australia and New Zealand and our recent introduction of UroShield to the European market. The next phase of the UM study is expected to be conducted concurrently with our preparations for the launch of UroShield in the U.S., subject to 510K clearance with the U.S. Food and Drug Administration.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/urology-devices-market\" class=\"ek-link\">Urology Devic<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/urology-devices-market\" class=\"ek-link\"><strong>es<\/strong><\/a><strong> <\/strong>&#8211; <strong>Market Insights, Competitive Landscape, and Market Forecast &#8211; 2030\u201d<\/strong>, the urology devices market was valued at <strong>USD 9.17 billion<\/strong> in 2023, growing at a <strong>CAGR<\/strong> of <strong>6.78%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 13.56 billion<\/strong> by 2030. The urology devices market is growing significantly due to the increasing cases of chronic disorders including cancers and benign prostatic hyperplasia (BPH), rising geriatric population prone to such conditions, technological advancements in product development, growing preference of minimally invasive procedures that are expected to escalate the demand for urology devices during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hologic-completed-the-acquisition-of-gynesonics-inc-nbsp\"><span class=\"ez-toc-section\" id=\"Hologic_Completed_the_Acquisition_of_Gynesonics_Inc\"><\/span>Hologic Completed the Acquisition of Gynesonics, Inc.&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>January 06<\/strong>, <strong>2025<\/strong>, Hologic, Inc., a global leader in women\u2019s health, completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics\u00ae), a privately held medical device company specializing in minimally invasive solutions for women\u2019s health, for approximately $350 million.<\/p>\n\n\n\n<p>The Sonata System is a technology designed for diagnostic intrauterine imaging and the transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. It combined real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.<em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/em><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;We are excited to complete the acquisition of Gynesonics and to increase access to their Sonata\u00ae System, which complements and expands our range of minimally invasive solutions for heavy periods and fibroids,\u201d <\/em>said Brandon Schnittker, President of Surgical Solutions at Hologic.<em> \u201cAs global champions for women\u2019s health, we are dedicated to empowering surgeons with diverse, cutting-edge treatment options as we strive to transform women\u2019s lives for the better.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cAs we embark on this new phase with Hologic, we are excited to see the continued success of the Sonata System, which has already made a difference in the lives of thousands of women,\u201d <\/em>said Skip Baldino, President and Chief Executive Officer of Gynesonics.<em> \u201cHologic\u2019s commitment to women\u2019s health and their leadership in innovation make them a perfect fit for our organization.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/gyneco-obstetric-ultrasound-systems-market\"><strong>Gyneco-Obstetric Ultrasound Systems<\/strong><\/a> <strong>&#8211; Market Insights, Competitive Landscape, and Market Forecast &#8211; 2030\u201d<\/strong>, the gyneco-obstetric ultrasound systems market was valued at <strong>USD 2.68 billion<\/strong> in 2023, growing at a <strong>CAGR<\/strong> of <strong>5.70%<\/strong> during the forecast period from 2024 to 2030, in order to reach <strong>USD 3.73 billion<\/strong> by 2030. The gyneco-obstetric ultrasound systems market is witnessing positive growth owing to factors such as the increasing instances of gynecological disorders such as pregnancies, ovarian cysts, fibroids, polycystic ovary syndrome, endometriosis and others, advancements in technology, and the increasing demand for comprehensive reproductive health monitoring among others that are acting as major factors driving the growth of the gyneco-obstetric ultrasound systems market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-movano-health-launched-evieai-virtual-wellness-assistant-nbsp\"><span class=\"ez-toc-section\" id=\"Movano_Health_Launched_EvieAI_Virtual_Wellness_Assistant\"><\/span>Movano Health Launched EvieAI Virtual Wellness Assistant&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>January 08<\/strong>, <strong>2025<\/strong>, Movano Health announced the latest enhancement to its Evie smart ring for women with the beta release of EvieAI, the first wearable-based virtual wellness assistant trained exclusively with data from medical journals. The new feature enabled Evie users to answer health questions quickly, reliably, and securely through the ring&#8217;s companion app.<\/p>\n\n\n\n<p>Planned future integration with Evie data was set to allow EvieAI&#8217;s responses to be personalized based on users&#8217; own health metrics, including heart rate, blood oxygen, menstrual cycle information, skin temperature variability, sleep, exercise, and mood captured by Evie&#8217;s sensors and user logs.<\/p>\n\n\n\n<p>Unlike general-purpose digital assistants like ChatGPT, which are trained using public data, EvieAI generated clear and concise answers based on articles published in over 100,000 medical journals and written by medical professionals. This helped ensure accuracy and the ability to interpret complex user queries about almost any symptom, disease, condition, or procedure.<\/p>\n\n\n\n<p>Evie&#8217;s new virtual assistant also followed industry-standard encryption protocols to ensure that all user data, including sensitive health information, was protected during storage and transmission. This included confidentiality protections ensuring that chats could not be traced back to individual users.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;Our vision for the Evie Ring has always been to provide insights that can help users navigate their personal wellness journeys,&#8221; <\/em>said Tyla Bucher, Chief Marketing Officer at Movano Health.<em> &#8220;EvieAI marks a significant leap forward in helping us fulfill that vision.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/womens-health-market\"><strong>Women\u2019s Health<\/strong><\/a><strong> &#8211; Market Insights, Competitive Landscape, and Market Forecast &#8211; 2030\u201d<\/strong>, the global women\u2019s health market was valued at <strong>USD 31.94 billion<\/strong> in 2023, growing at a <strong>CAGR<\/strong> of <strong>5.40%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 43.76 billion<\/strong> by 2030. The women\u2019s health market is slated to witness prosperity owing to factors such as the growing prevalence of breast cancer, further rise in menstrual disorders and infertility issues in women, and the growing focus on improving the safety, affordability, and usability of women\u2019s health products are further expected to result in the appreciable revenue growth in the women\u2019s health market during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche&#8217;s Momentum in Digital Pathology Continued With FDA Clearance on its High-Volume Slide Scanner&nbsp; On January 09, 2025, Roche announced that its whole slide imaging system, Roche Digital Pathology Dx, received an additional 510(k) clearance from the United States Food and Drug Administration (FDA). This clearance modified the one Roche had previously obtained on June [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30767,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[21807,21442,1501,2753,17021,16975,19033,937,20113,20112,17667,19003,20358],"industry":[17226],"therapeutic_areas":[17245,17411],"class_list":["post-30766","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-diagnostic-imaging-equipment","tag-gyneco-obstetric-ultrasound-systems","tag-infertility","tag-medical-device","tag-medical-devices-market","tag-medtech-market","tag-spinal-cord-stimulators","tag-urinary-tract-infections","tag-urology-devices","tag-urology-devices-market","tag-uterine-fibroids","tag-womens-health","tag-womens-health-market","industry-medical-devices","therapeutic_areas-neurology","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Roche, NanoVibronix, Hologic<\/title>\n<meta name=\"description\" content=\"Roche&#039;s scanner; Pacira\u2019s Iovera\u00b0; ClearCut shares results; NanoVibronix completes pilot; Hologic buys Gynesonics; Movano launches EvieAI.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Roche, NanoVibronix, Hologic\" \/>\n<meta property=\"og:description\" content=\"Roche&#039;s scanner; Pacira\u2019s Iovera\u00b0; ClearCut shares results; NanoVibronix completes pilot; Hologic buys Gynesonics; Movano launches EvieAI.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T12:34:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T12:34:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/09180001\/medtech-news-of-roche-nanovibronix-hologic.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Roche, NanoVibronix, Hologic","description":"Roche's scanner; Pacira\u2019s Iovera\u00b0; ClearCut shares results; NanoVibronix completes pilot; Hologic buys Gynesonics; Movano launches EvieAI.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Roche, NanoVibronix, Hologic","og_description":"Roche's scanner; Pacira\u2019s Iovera\u00b0; ClearCut shares results; NanoVibronix completes pilot; Hologic buys Gynesonics; Movano launches EvieAI.","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-01-09T12:34:26+00:00","article_modified_time":"2025-01-09T12:34:27+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/09180001\/medtech-news-of-roche-nanovibronix-hologic.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic","name":"MedTech News | Roche, NanoVibronix, Hologic","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/09180001\/medtech-news-of-roche-nanovibronix-hologic.png","datePublished":"2025-01-09T12:34:26+00:00","dateModified":"2025-01-09T12:34:27+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Roche's scanner; Pacira\u2019s Iovera\u00b0; ClearCut shares results; NanoVibronix completes pilot; Hologic buys Gynesonics; Movano launches EvieAI.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-of-roche-nanovibronix-hologic#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/09180001\/medtech-news-of-roche-nanovibronix-hologic.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/09180001\/medtech-news-of-roche-nanovibronix-hologic.png","width":772,"height":482,"caption":"medtech-news-of-roche-nanovibronix-hologic"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/09180001\/medtech-news-of-roche-nanovibronix-hologic-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diagnostic Imaging Equipment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gyneco-Obstetric Ultrasound Systems<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Infertility<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Cord Stimulators<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Urinary Tract Infections<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Urology Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Urology Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Uterine Fibroids<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">women\u2019s health<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Women\u2019s Health Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Diagnostic Imaging Equipment<\/span>","<span class=\"advgb-post-tax-term\">Gyneco-Obstetric Ultrasound Systems<\/span>","<span class=\"advgb-post-tax-term\">Infertility<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Spinal Cord Stimulators<\/span>","<span class=\"advgb-post-tax-term\">Urinary Tract Infections<\/span>","<span class=\"advgb-post-tax-term\">Urology Devices<\/span>","<span class=\"advgb-post-tax-term\">Urology Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Uterine Fibroids<\/span>","<span class=\"advgb-post-tax-term\">women\u2019s health<\/span>","<span class=\"advgb-post-tax-term\">Women\u2019s Health Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jan 9, 2025","modified":"Updated on Jan 9, 2025"},"absolute_dates_time":{"created":"Posted on Jan 9, 2025 6:04 pm","modified":"Updated on Jan 9, 2025 6:04 pm"},"featured_img_caption":"medtech-news-of-roche-nanovibronix-hologic","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30766"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30766\/revisions"}],"predecessor-version":[{"id":30768,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30766\/revisions\/30768"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30767"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30766"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30766"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}